(Q86716365)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676488%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

The role of nonrandomized trials in the evaluation of oncology drugs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676488%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

R Simon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676488%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

G M Blumenthal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676488%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M L Rothenberg

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676488%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

J Sommer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676488%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

S A Roberts

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676488%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

D K Armstrong

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676488%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

L M LaVange

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676488%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

R Pazdur

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676488%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

7 April 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676488%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676488%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

97

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676488%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676488%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

502-507

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676488%20AND%20SRC:MED&resulttype=core&format=json

End points and United States Food and Drug Administration approval of oncology drugs

29 February 2020

cites work

1 reference

7 January 2021

Cancer: the road to Amiens

1 reference

7 January 2021

Role of randomized phase III trials in an era of effective targeted therapies

1 reference

7 January 2021

Assessing the measure of a new drug: is survival the only thing that matters?

1 reference

7 January 2021

Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases

1 reference

7 January 2021

U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma

1 reference

7 January 2021

When progressive disease does not mean treatment failure: reconsidering the criteria for progression

1 reference

7 January 2021

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology

1 reference

7 January 2021

Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy

1 reference

7 January 2021

Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009

1 reference

7 January 2021

Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies

1 reference

7 January 2021

Conditional power calculations for clinical trials with historical controls.

1 reference

7 January 2021

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

1 reference

7 January 2021

Accelerated approval of oncology products: the food and drug administration experience

1 reference

7 January 2021

Optimizing dosing of oncology drugs

1 reference

7 January 2021

Identifiers

DOI

10.1002/CPT.86

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25676488%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference